5 factors to acknowledge previous to the securities market opens up Monday

Listed here are one of the important story that capitalists require to start their buying and selling day:

Inventory futures ticked larger Monday after equities toppled lately. The S&P 500 dropped 4.3% for the period, its worst week since 2023. The Nasdaq Composite shed 5.8% in its poorest week since 2022, and the Dow Jones Industrial Average fell 2.9%. Investors will be watching this week for inflation data, which could help to determine how large of a rate cut the Federal Reserve makes at its policy meeting later this month. The central bank is widely expected to trim its target rate by at least a quarter of a percentage point. The consumer price index due Wednesday and producer price index set for Thursday will help shape the Fed’s decision. Follow live market updates.

Norfolk Southern‘s board is looking into allegations that CEO Alan Shaw had an inappropriate workplace relationship, three people familiar with the matter told CNBC. The rail operator later said it is investigating “possible conduct” that violates its code of ethics and has outside hired legal counsel for a probe. The investigation is only the latest turmoil at Norfolk Southern, following a toxic train derailment in Ohio and a proxy fight with activist investor Ancora. Shaw did not return calls or text messages requesting comment.

Boeing reached a labor agreement with a union that represents roughly 33,000 of its workers, potentially preventing a costly strike. The tentative agreement, which still needs approval from workers, includes 25% raises over four years, according to the International Association of Machinists and Aerospace Workers. The current deal was set to expire after Thursday. In a statement, the union said its workers will help to “bring this company back on track” after a string of missteps. Stephanie Pope, chief executive of Boeing’s commercial airplane unit, also lauded the pay increases and benefit improvements in the deal.

The Alzheimer’s treatment Leqembi from Biogen and Eisai is considered a breakthrough in slowing the progression of the mind-damaging disease. CNBC spoke to patients about their experience in receiving the drug since its rollout last year, which has been hampered by the complicated process to get diagnosed and treated. One patient said Leqembi is “extending my time of a normal life.” The treatment comes with drawbacks, like the risk of brain swelling or bleeding.